Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;10(1):292-299.
doi: 10.21037/tau-20-959.

Efficacy and safety of tigecycline for complicated urinary tract infection: a systematic review

Yang-Xi Liu  1 , Ke-Jia Le  1 , Hong-Yao Shi  2 , Zai-Li Zhang  1 , Min Cui  1 , Han Zhong  1 , Yue-Tian Yu  3 , Zhi-Chun Gu  1
Affiliations

Efficacy and safety of tigecycline for complicated urinary tract infection: a systematic review

Yang-Xi Liu et al. Transl Androl Urol. 2021 Jan.

Abstract

Background: Facing the global threat of emerging resistance to antibiotics, tigecycline, a novel glycylcycline antibiotic, is developed to against multidrug-resistant pathogens, but not recommended for the treatment of complicated urinary tract infection (cUTI). We performed a summary of the literatures to characterize and evaluate the efficacy and safety of tigecycline in patients with cUTI.

Methods: We searched PubMed, EMBASE, Cochrane and Clinical Trials using appropriate syntax to retrieve potential articles up to Jan 2020. General information, pathogen, medication regimen, comorbidities of patients from eligible literatures were recorded. Univariate logistic regression analysis was used to detect the potential factors associated with clinical cure.

Results: Nineteen articles comprising 31 cases were included. The subpopulation with transplantation (25.8% of the patients) was the most common comorbidity, and cUTIs were mainly caused by Klebsiella pneumoniae (K. pneumoniae) (48.28%) in our research. Tigecycline 100 mg per day as monotherapy was most common. Clinical cure was reported as majority (77.4%), and microbiological eradication cases accounted for the most (65.2%) among the clinical cure cases. Univariate analysis showed that K. pneumoniae caused cUTI and tigecycline as a single treatment have significant meaning to clinical outcomes (P=0.044 and P=0.034, respectively).

Conclusions: Clinical and microbiological outcomes of tigecycline treatment revealed high rate of successful response. Tigecycline monotherapy may have a role in the treatment of cUTI except that caused by the pathogen K. pneumoniae. Further randomized controlled trials was still needed to evaluate tigecycline monotherapy for cUTI.

Keywords: Klebsiella pneumoniae (K. pneumoniae); Tigecycline; antibiotics; complicated urinary tract infection (cUTI); systematic review.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau-20-959). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Flow diagram of articles selection. Articles published in PubMed, Embase, Cochrane and Clinical Trials were searched and selected.
Figure 2
Figure 2
Flow diagram of outcome. The clinical and microbiological outcome of 31 cases in 19 articles.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rodrigues dos Santos BG, Amaral ES, Fernandes PFCBC, et al. Urinary Tract Infections and Surgical Site Infections due to Carbapenem-Resistant Enterobacteriaceae in Renal Transplant. Transplant Proc 2016;48:2050-5. 10.1016/j.transproceed.2016.05.005 - DOI - PubMed
    1. Brust K, Evans A, Plemmons R. Tigecycline in treatment of multidrug-resistant Gram-negative bacillus urinary tract infections: A systematic review. J Antimicrob Chemother 2014;69:2606-10. 10.1093/jac/dku189 - DOI - PubMed
    1. Tasina E, Haidich AB, Kokkali S, et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011;11:834-44. 10.1016/S1473-3099(11)70177-3 - DOI - PubMed
    1. Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 2019;39:10-39. 10.1002/phar.2209 - DOI - PMC - PubMed
    1. Meagher AK, Ambrose PG, Grasela TH, et al. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005;41 Suppl 5:S333-40. 10.1086/431674 - DOI - PubMed

LinkOut - more resources